Showing 861 - 880 results of 102,005 for search '(( 50 point decrease ) OR ( 5 ((((wt decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.39s Refine Results
  1. 861
  2. 862
  3. 863

    Stability parameters for SpGrx3 WT and mutants. by Trang Van Tran (16913946)

    Published 2023
    “…Hydrophilic-to-hydrophobic substitutions were made in the aromatic cluster, in β1 (E5V and Y7F), adjacent β2 (Y32F and Y32L), both β1 and β2 (E5V/Y32L), and short α2 (R47F). …”
  4. 864

    Kinetic parameters of SpGrx3 WT and mutants. by Trang Van Tran (16913946)

    Published 2023
    “…Hydrophilic-to-hydrophobic substitutions were made in the aromatic cluster, in β1 (E5V and Y7F), adjacent β2 (Y32F and Y32L), both β1 and β2 (E5V/Y32L), and short α2 (R47F). …”
  5. 865
  6. 866
  7. 867
  8. 868

    Decrease of locomotor activity in <i>Auts2</i> mutant mice during habituation. by Kei Hori (840871)

    Published 2016
    “…<p>(A) Spontaneous locomotor activity for habituation to the novel environment was measured every 5 min for 60 min. …”
  9. 869
  10. 870

    Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  11. 871

    Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  12. 872

    Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  13. 873

    Image1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  14. 874

    Image3_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  15. 875

    Image7_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  16. 876

    Table1_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.xlsx by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  17. 877

    Quantitation of seeding activity in brain tissue from a sporadic CJD patient using end-point RT-QUIC. by Hanae Takatsuki (754161)

    Published 2015
    “…<p>(a) BH (Pt 1) was diluted (5 × 10<sup>–5</sup> to 5 × 10<sup>–9</sup>) and subjected to RT-QUIC reaction containing human recPrP substrate. …”
  18. 878

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  19. 879
  20. 880